FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, namely to ophthalmology, and is intended for the treatment of uveitis and macular edema in the subject. For the treatment of these diseases in the subject, a composition containing an effective amount of an antibody that specifically binds IL-6 receptor is used. Said subject has a vitreous haze (VH) level of 2 on the Miami 9-Grade Scale or greater, or said subject has a central retinal thickness (CRT) greater than 300 μm. An antibody that specifically binds to IL-6 receptor contains a sequence of a variable heavy chain site under SEQ ID NO: 2 and a sequence of a variable light chain site under SEQ ID NO: 3. The antibody is administered at a dose of 150 to 200 mg once every two weeks.
EFFECT: use of the group of inventions makes it possible to increase the effectiveness of uveitis and macular edema treatment in the subject.
18 cl, 16 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS | 2020 |
|
RU2828027C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| IL-6 RECEPTOR ANTIBODY FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | 2020 |
|
RU2822089C2 |
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS FOR NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2014 |
|
RU2728578C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| METHODS OF TREATING CHRONIC POUCH ILEITIS | 2018 |
|
RU2822135C2 |
| METHOD OF TREATMENT OF ATOPIC DERMATITIS THROUGH INTRODUCTION OF IL-4R INHIBITOR | 2019 |
|
RU2801204C2 |
